Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies

dc.contributor.authorEhlert, Katerina
dc.contributor.authorHeinze, Birgit
dc.contributor.authorGraham, Marien Alet
dc.contributor.authorSwanepoel, De Wet
dc.date.accessioned2023-02-22T12:58:02Z
dc.date.available2023-02-22T12:58:02Z
dc.date.issued2023-01
dc.description.abstractOBJECTIVE : This study investigated mobile health enabled surveillance in ototoxicity. METHOD : This was a longitudinal study of 32 participants receiving chemotherapy. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient's treatment venue using a validated mobile health audiometer. RESULTS : Average hearing thresholds at baseline were within the normal range (81.2 per cent left; 93.8 per cent right), reducing at exit testing (71.9 per cent left; 78.1 per cent right). Half of participants presented with a threshold shift according to ototoxicity monitoring criteria. The frequencies affected the most were between 4000 and 16 000 Hz, with left ears significantly more affected than right ears. Noise levels exceeded the maximum permissible ambient noise levels in up to 43.8 per cent of low frequencies (250–1000 Hz). CONCLUSION : Mobile health supported audiometry proved to be an efficacious tool for ototoxicity monitoring at the treatment venue. Changes in hearing ability over time could be tracked, improving surveillance in patients with full treatment schedules.en_US
dc.description.departmentScience, Mathematics and Technology Educationen_US
dc.description.departmentSpeech-Language Pathology and Audiologyen_US
dc.description.librarianhj2023en_US
dc.description.urihttps://www.cambridge.org/core/journals/journal-of-laryngology-and-otologyen_US
dc.identifier.citationEhlert, K., Heinze, B., Graham, M., & Swanepoel, D. (2023). Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies. The Journal of Laryngology & Otology, 137(1), 61-67. doi: 10.1017/S0022215122001281.en_US
dc.identifier.issn0022-2151 (print)
dc.identifier.issn1748-5460 (online)
dc.identifier.other10.1017/S0022215122001281
dc.identifier.urihttps://repository.up.ac.za/handle/2263/89768
dc.language.isoenen_US
dc.publisherCambridge University Pressen_US
dc.rights© The Author(s), 2022. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectChemotherapy agenten_US
dc.subjectCanceren_US
dc.subjectCarboplatinen_US
dc.subjectCisplatinen_US
dc.subjectOxaliplatinen_US
dc.subjectHearing disorderen_US
dc.subjectOtotoxicityen_US
dc.subjectDrug induceden_US
dc.titleSurveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequenciesen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ehlert_Surveillance_2022.pdf
Size:
210.28 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: